Industry ranking
MUNDIPHARMA INTERNATIONAL LIMITED exhibits a consistent trend of extended payment cycles, with an average payment time of 118 days. A substantial 65% of payments are made after 30 days, including 25% extending beyond 60 days, indicating a deliberate and consistently slow payment speed rather than rapid fluctuations.
The payment data suggests a predictable slowness rather than high unpredictability, as the majority of payments consistently fall into longer timeframes. While only 7% are formally 'late', the high average payment time of 118 days points to a reliable pattern of delayed disbursements, posing a consistent cash flow strain rather than sporadic volatility.
Suppliers should anticipate significantly extended payment terms when dealing with MUNDIPHARMA INTERNATIONAL LIMITED, requiring robust working capital management. Key decision factors include the supplier's capacity to absorb long payment cycles; consider negotiating shorter payment terms or adjusting pricing to account for the average 118-day cycle to mitigate cash flow risks.
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2024 - 31 Dec 2024 | 19 Feb 2025 | 69 | 54% | 31% | 15% | 47% |
| 01 Jan 2024 - 30 Jun 2024 | 31 Jul 2024 | 118 | 35% | 40% | 25% | 7% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
The default position is 90 days, however there may be changes to this default position on a case-by-case basis pending agreement with suppliers. On a case-by-case basis, payment terms to suppliers may be immediate payment or payment on terms within 7, 14, 30 or 60 days.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
90
If suppliers have a query or dispute relating to a payment they believe is owed to them by MINT, they will need to email the following details below, to MINT.APQueries@mundipharma.com a. Full supplier name, address. b. The name of your MINT point of contact. c. Invoice number for the payment you are querying. d. Full details of your complaint. Upon receipt of all the above details, MINT commits to acknowledge receipt of your email within five working days and may request further information to be able to respond in full. MINT will investigate your query using the details provided and speak with relevant members of MINT’s business, including members of MINT’s legal department if necessary, and respond in full within 14 days of the date of MINT’s acknowledgement to you.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Mundipharma International Limited is a UK-registered company based at Cambridge Science Park, incorporated in 1992. Its registered activity is management consultancy other than financial management, and it forms part of the wider Mundipharma organisation, described on its website as a global group focused on pharmaceuticals and patient care. The wider Mundipharma group develops and supplies medicines and consumer health products, with a stated focus on patient centricity and ESG commitments. This UK entity operates within that global structure rather than as an independent trading pharmaceutical manufacturer, reflecting its consultancy-related registration while being connected to Mundipharma's broader pharmaceutical and healthcare activities described on the group website.
Generated from the company's website and Companies House records. Sources: bardpharmaceuticals.co.uk